December 15, 2016 | Cancer and Blood Disorders, ResearchComments Off on New Trial Hopes to Increase Survival for Kids With Cancer, Reduce Risk of Long Term Cardiac Damage
Dr. Todd Cooper, director of the Pediatric Leukemia/Lymphoma Program and Evans Family Endowed Chair in Pediatric Cancer at Seattle Children’s, is leading a new clinical trial for children and adolescents with AML.
Imagine conquering childhood cancer, only to find out that years down the road your heart may fail. Unfortunately, many children who have battled cancer face this reality. While often lifesaving, the effects of chemotherapy treatment (drugs that kill cancer cells) can take a toll on the developing body of a child, potentially resulting in life-threatening late side effects like cardiac damage.
“You go through terrible chemotherapy, achieve remission, have a new lease on life and then your heart fails,” said Dr. Todd Cooper, director of the Pediatric Leukemia/Lymphoma Program and Evans Family Endowed Chair in Pediatric Cancer at Seattle Children’s. “It’s not fair, and we’re determined to change this reality.” Read full post »
Reef, 16 months old, poses for a photo with Richard Sherman.
Blue Tuesday at Seattle Children’s was a little more spirited today thanks to a special visit from the Seattle Seahawks players and members of the Sea Gals. Patients and families were all smiles as they got to meet their favorite football players during the team’s annual Captain’s Blitz visit.
“It was so exciting,” said Joanna Gromadzki. Gromadzki’s 16-month-old son, Reef Gromadzki-Johnson, has been a patient since he was 2 months old after he was diagnosed with pulmonary vein stenosis. “Seattle Children’s is like a second home to us, we’ve been here for so long. Today was special. We’re huge fans of the Seahawks!”
The Seahawks visit really brightened the day for Reef and other 12s in the hospital, and brought holiday cheer to some young and loyal fans. Read full post »
Dr. Rebecca Gardner, oncologist and lead investigator for Seattle Children’s PLAT-02 trial.
T-cell immunotherapy continues to take center stage as one of the most promising new cancer therapies of our time. After receiving the therapy, which reprograms a person’s own T cells to detect and destroy cancer, 93% of children with acute lymphoblastic leukemia (ALL) who enrolled in Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) trial and were unlikely to survive, achieved complete remission. Some are still in remission now more than two years out from the therapy.
This is a message that Dr. Rebecca Gardner, oncologist and lead investigator for the PLAT-02 trial at Seattle Children’s, will be underscoring in her abstract presentations at The American Society of Hematology (ASH) Annual Meeting. However, she will also highlight that there is still work to be done, and will present a possible answer to one of the most challenging puzzles facing researchers in the field: How can we limit the possible side effects of the treatment while retaining the effectiveness of the T cells?
“We are in a pivotal time where we know this therapy works in getting patients who are very sick into remission, but now we’re focusing on how to improve the treatment experience, which includes limiting the possible side effects,” said Gardner. “Our latest results mark an exciting milestone where we have potentially found the key to better controlling the body’s reaction to the T cells while still ensuring efficacy.” Read full post »
Greta Oberhofer’s leukemia is in remission thanks to T-cell immunotherapy developed at Seattle Children’s.
Greta Oberhofer survived a bone marrow transplant for leukemia when she was just 8 months old — but the side effects nearly killed her. Then, six months later, her family’s worst fears came to life.
“My husband put the doctor on speaker phone — he told me Greta relapsed and that her prognosis was bad,” remembers her mother, Maggie Oberhofer. “She had already suffered so much with the chemotherapy and transplant, and we didn’t want to put her through that again. We didn’t know what to do.”
The Oberhofers — who live in Portland — were considering hospice for Greta. Then they heard that Seattle Children’s Dr. Rebecca Gardner was testing a therapy that uses reprogrammed immune cells to attack certain kinds of leukemia.
“Dr. Gardner said not to give up because her therapy was putting kids like Greta in remission, and that the side effects were often a lot easier to tolerate,” Oberhofer says. “We suddenly had a way forward.”
A few months later, the Oberhofers watched Greta’s reprogrammed cells drip into her body. Two weeks after that, her cancer was in remission.
In December of last year, Laura Coffman began to notice that something wasn’t quite right with her 2-year-old son, Hunter. He was leaning to one side and seemed to lose his balance easily. When he became lethargic and started vomiting a few days later on Dec. 28, she knew it was time to see the pediatrician.
After all standard tests came back normal, they were sent to Seattle Children’s for further testing and to find an answer. Unfortunately, it was far worse than anything Coffman could have imagined.
“What I thought was probably just Hunter being a wobbly toddler with a virus turned out to be a brain tumor,” said Coffman. “I will never forget that day. It was the most traumatic six hours of our lives.” Read full post »
He may not be able to fly, or be as fast as the speed of light, but for children who have been diagnosed with cancer at Seattle Children’s, the cuddly teddy bear who wears a mask and purple cape is still a super hero to them – he gives them strength. His name is T-Bear and he’s bringing hope to children with cancer.
Meet T-Bear, He’s more than just a teddy bear
Catherine Lindgren, director of the Therapeutic Cell Production Core (TCPC) and its’ team at Seattle Children’s Research Institute, had an idea to make a life-changing moment feel a little more personal for cancer patients undergoing immunotherapy, a new treatment that harnesses a patient’s own immune system to seek and destroy cancer. Lindgren wanted every child to know they aren’t alone – that they have a team of support around them. And so, T-Bear was born.
“Teddy bears are historically comforting to sick children,” said Lindgren. “We wanted families to know we’re on their team, and together, we’re Strong Against Cancer.” Read full post »
What is covered in spots, red and blue stripes, has a skyline and a music scale? The answer: Kasey Kahne’s newest No. 5 race car. This July at Daytona International Speedway, Kahne will drive the Hendrick Motorsports No. 5 Great Clips Chevrolet SS with a very special paint scheme that’s guaranteed to turn a few heads. But, what makes the car truly unique is the fact that it was designed by 8-year-old Noelia Gutierrez, a cancer patient at Seattle Children’s.
Noelia’s car design was inspired by all her favorite things – Barcelona FC soccer team, jaguars, singing and Seattle’s iconic skyline.
Her hope is that all of her favorite things will inspire Kahne as he races to reach the checkered flag. Read full post »
Katie Belle, now 10 years old, was diagnosed with high-risk neuroblastoma when she was 3.
In August of 2009, when Katie Belle was just 3 1/2 years old, a persistent fever led her to Seattle Children’s Emergency Department where doctors discovered a baseball-sized tumor in her abdomen. She was diagnosed with high-risk neuroblastoma, a cancer that starts in immature nerve cells and develops into tumors. Her chance of survival: 35%.
“I felt like someone stuck a dagger in my stomach,” said Katie’s mother, Jennifer Belle. “I couldn’t breathe. However, I had to put on a brave face for Katie.”
For children with high-risk neuroblastoma, which according to the National Cancer Institute occurs in approximately one out of 100,000 children, Katie’s prognosis was not uncommon. On average, less than 50% of children with this disease live five or more years after diagnosis.
However, a Phase 3 trial performed by the Children’s Oncology Group (COG), and led by Seattle Children’s oncologist Dr. Julie Park, has found that adding a second autologous stem-cell transplant, which is a transplant that uses the patient’s own stem cells, to standard therapy improves outcomes for patients with high-risk neuroblastoma. Read full post »
“As a parent, you never want to hear that your child has cancer,” said Paul Esposito, of Plano, Texas. “It creates an emotion that starts at your feet and takes hold. It’s devastating.”
This was the terrible news Paul and his family received in 2010 when his son, Zane Esposito, was only 7 years old. Zane, now 12, was diagnosed with acute lymphoblastic leukemia (ALL) in June 2010. Zane underwent three grueling years of cancer treatment, including 365 days of chemotherapy, before reaching remission. Two years later, Zane relapsed in January of this year. Their only option: another three years of aggressive chemotherapy.
“I really don’t like chemo, it’s the worst,” said Zane. “My back hurt super bad due to tiny fractures from the chemo. I couldn’t even bend over to tie my shoes. And here I was having to start another three years all over again.”
Not only was the thought of starting over daunting, but Zane faced a major hurdle as he began chemotherapy – his cancer was not responding to the treatment. He had refractory ALL. Zane and his family were desperate for another treatment option.
About 2,000 miles away in Seattle, Wash., they would find that other option. But first, they would learn about it in the most unlikely place: a doughnut shop. Read full post »
Seattle Children's complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.